Free Trial
NASDAQ:IMUX

Immunic (IMUX) Stock Price, News & Analysis

Immunic logo
$0.87 -0.03 (-3.35%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.88 +0.01 (+1.36%)
As of 08/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunic Stock (NASDAQ:IMUX)

Key Stats

Today's Range
$0.83
$0.94
50-Day Range
$0.69
$1.12
52-Week Range
$0.56
$2.11
Volume
1.06 million shs
Average Volume
1.09 million shs
Market Capitalization
$83.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

Immunic Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

IMUX MarketRank™: 

Immunic scored higher than 54% of companies evaluated by MarketBeat, and ranked 478th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunic has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunic has only been the subject of 3 research reports in the past 90 days.

  • Read more about Immunic's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunic are expected to grow in the coming year, from ($0.94) to ($0.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunic is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunic is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunic has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.93% of the outstanding shares of Immunic have been sold short.
  • Short Interest Ratio / Days to Cover

    Immunic has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Immunic has recently decreased by 4.36%, indicating that investor sentiment is improving.
  • Dividend Yield

    Immunic does not currently pay a dividend.

  • Dividend Growth

    Immunic does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.93% of the outstanding shares of Immunic have been sold short.
  • Short Interest Ratio / Days to Cover

    Immunic has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Immunic has recently decreased by 4.36%, indicating that investor sentiment is improving.
  • News Sentiment

    Immunic has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Immunic this week, compared to 3 articles on an average week.
  • Search Interest

    40 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,150.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Immunic is held by insiders.

  • Percentage Held by Institutions

    51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunic's insider trading history.
Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

IMUX Stock News Headlines

Immunic (IMUX) Q2 Loss Widens 25%
China's 500 Million Year Advantage
The "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMOLISHED Google's record using pure light particles instead of exotic superconductors. The secret? A revolutionary material that ONE American company is the first to commercially produce.
Immunic advances MS drug program with Phase 3 trials fully enrolled
See More Headlines

IMUX Stock Analysis - Frequently Asked Questions

Immunic's stock was trading at $1.00 at the start of the year. Since then, IMUX shares have decreased by 12.8% and is now trading at $0.8721.

Immunic, Inc. (NASDAQ:IMUX) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.02.

Top institutional investors of Immunic include Aberdeen Group plc (8.60%) and Simplex Trading LLC. Insiders that own company stock include Richard Alan Rudick, Duane Nash, Daniel Vitt, Glenn Whaley and Joerg Neermann.
View institutional ownership trends
.

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX).

Company Calendar

Last Earnings
8/07/2025
Today
8/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMUX
CIK
1280776
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+760.0%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$100.51 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-562.00%
Return on Assets
-242.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.74
Quick Ratio
0.74

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
4.36

Miscellaneous

Outstanding Shares
95,820,000
Free Float
91,410,000
Market Cap
$83.56 million
Optionable
Optionable
Beta
1.39

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:IMUX) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners